May 6 |
Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal
|
Apr 8 |
Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services
|
Mar 12 |
Scinai leadership to attend BIO-Europe Spring 2024
|
Feb 29 |
Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024
|
Jan 30 |
Scinai Immunotherapeutics files to sell 5.36M ADS for holders
|
Jan 25 |
Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize
|
Jan 4 |
Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds
|
Jan 4 |
Scinai Immunotherapeutics CEO Issues Letter to Shareholders
|
Dec 27 |
Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9
|
Dec 12 |
Scinai Announces Promising Results in a Psoriatic Human Skin Model
|